Xilio Therapeutics Reports Officer/Director Changes, Comp Arrangements
Ticker: XLO · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1840233
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Xilio Therapeutics just filed an 8-K hinting at leadership changes and new pay deals.**
AI Summary
Xilio Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on January 1, 2024, related to the departure or election of directors/officers and their compensatory arrangements. This filing indicates potential changes in leadership or executive compensation, which could impact the company's strategic direction and financial health. Investors should monitor subsequent filings for specific details on who departed or was appointed and the terms of any new compensation plans, as these changes can signal shifts in company strategy or financial stability.
Why It Matters
Changes in leadership and executive compensation can significantly influence a company's future performance and investor confidence. New leadership might bring fresh strategies, while revised compensation could impact financial overhead.
Risk Assessment
Risk Level: medium — The filing indicates changes in leadership or compensation, which can introduce uncertainty regarding future company direction and financial commitments, warranting a medium risk assessment until specific details are disclosed.
Analyst Insight
Investors should await further disclosures from Xilio Therapeutics regarding the specific personnel changes and compensation details to fully assess the impact on the company's strategy and financial outlook before making investment decisions.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for Xilio Therapeutics, Inc.
- 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 (company) — principal executive offices of Xilio Therapeutics, Inc.
Forward-Looking Statements
- Xilio Therapeutics will provide specific details about the director/officer changes and compensation arrangements in a subsequent filing or press release. (Xilio Therapeutics, Inc.) — high confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 1, 2024.
What specific items are covered in this 8-K filing according to the 'ITEM INFORMATION' section?
The 'ITEM INFORMATION' section indicates that the filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
What is the business address of Xilio Therapeutics, Inc. as stated in the filing?
The business address of Xilio Therapeutics, Inc. is 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
What is the Commission File Number for Xilio Therapeutics, Inc.?
The Commission File Number for Xilio Therapeutics, Inc. is 001-40925.
When was this 8-K filing filed with the SEC?
This 8-K filing was filed with the SEC on January 3, 2024.
Filing Stats: 597 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-01-03 16:05:20
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share XLO Nasdaq Global Select
Filing Documents
- xlo-20240101x8k.htm (8-K) — 44KB
- xlo-20240101xex10d1.htm (EX-10.1) — 40KB
- 0001558370-24-000031.txt ( ) — 214KB
- xlo-20240101.xsd (EX-101.SCH) — 3KB
- xlo-20240101_lab.xml (EX-101.LAB) — 16KB
- xlo-20240101_pre.xml (EX-101.PRE) — 10KB
- xlo-20240101x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Restricted Stock Unit Agreement under 2021 Stock Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XILIO THERAPEUTICS, INC. Date: January 3, 2024 By: /s/ Chris Frankenfield Chris Frankenfield Chief Operating Officer